natgillin/translations-raw huggingface dataset:
A pyrazolo pyridine derivative according to any one of claims 1 to 9 for use in the prophylaxis or treatment of a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system, angiogenesis, angiogenesis-dependent conditions and other diseases and/or disorders associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). 
Derivat pirazol piridina prema bilo kom patentnom zahtjevu od 1 do 12, za upotrebu u tretmanu bolesti ili stanja izabranih iz grupe koju čine kardiovaskularni poremećaji, respiratorni poremećaji, poremećaji metabolizma, poremećaji na koži, poremećaji u kostima, neuroupalni i/ili neurodegenerativni poremećaji, oboljenja bubrega, poremećaji u reprodukciji, bolesti koje utječu na oko i/ili leću oka i/ili stanja koja utječu na unutrašnje uho, upalni poremećaji, bolesti jetre, bol, rak, alergijski poremećaji, ozlijede, septički, hemoragični 1 anafilaktički šok, bolesti i poremećaji gastrointestinalnog sistema, angiogeneza, stanja koja su uvjetovana angiogenezom, kao i druga oboljenja i/ili poremećaji koje karakterizira izmijenjena aktivnost ili funkcija oksidaze nikotinamid adenin dinukleotid fosfata (NADPH oksidaze).
a chimeric antibody comprising a light chain sequence comprising the amino acid sequence SEQ ID No. 
kimerno antitijelo koje sadrži sekvenciju lakog lanca koji sadrži aminokiselinsku sekvenciju SEQ ID No.
is a direct bonded or —O-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl; 
R' je direktno vezan ili preko kisika vezan zasićen, djelomično zasićen ili nezasićen 5-, 6- ili 7-člani monociklični prsten koji sadrži 0, 1, 2, 3 ili 4 atoma izabrana od N, O 1 S, ali koji sadrži ne više od jednog O ili S, gdje su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R? supstituenta, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, Ci. aalkil, OC,alkil, OC, ghaloalkil, NHC,alkil, N(C,galkiDC,alkil i C,aghaloalkil;
a pharmaceutically acceptable phenolic preservative; and an amount of zinc sufficient to cause the PEGylated insulin lispro compounds to hexamerize. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži farmaceutski prihvatljiv fenolni konzervans 1 količinu cinka dovoljnu za heksameriziranje PEGiliranih spojeva inzulina lispro.
The method of claim 1, further comprising a fourth input for receiving address data and wherein forwarding comprises forwarding the conditionally modified firing signal to a selected one of a plurality of nozzle circuits of the nozzle group, the selected nozzle circuit being identified by the address data. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u primitku adresnih podataka, te što se slanje sastoji u slanju uvjetno modificiranog okidnog signala u odabrani između više mlazničnih krugova (334) u skupini mlaznica, gdje odabrani mlaznični krug (34) identificiraju adresni podaci.
The method according to claim 24, comprising replacing codon No. 
Postupak u skladu s patentnim zahtjevom 24, naznačen time što se sastoji u zamjeni kodona br.
The method according to claim 6, wherein said control sample is obtained from one or more subjects who are disease free or who have not been diagnosed with a WEE1 kinase associated cancer. 
Inhibitor WEE1 za upotrebu prema patentnom zahtjevu 6, gdje je navedeni kontrolni uzorak dobiven od jednog ili više subjekata koji nemaju bolest ili kod kojih nije dijagnostificiran karcinom povezan sa WEE1 kinazom.
The computer program product of claim 9, wherein the mobile operator is configured to check an account balance and/or charge protocols of the mobile phone account for payment for the goods or services and additional charges levied by the mobile operator. 
Proizvod računalni program prema bilo kojem od zahtjeva 9 do 11, dalje sadržeći povećanje računa mobilnog telefona korisnika (102) da uključuje saldo za plaćanje roba 1li usluga (105) od trgovca (104).
10 shows an alternative embodiment of a heat exchanger 70 where the cooling channel comprises a number of loops 86, 87, where the seal 89 made of flexible material, such as, for example, rubber or silicones, comprises a number of fingers 90, 91 located between the loops 86, 87 for a liquid-tight seal. 
10 prikazuje alternativnu izvedbu izmjenjivača topline 70 gdje kanal za hlađenje sadrži niz petlji 86, 87, pri čemu je brtva 89 načinjena od fleksibilnog materijala, kao što je, na primjer, guma ili silikonski materijal, te uz to sadrži niz prstiju 90, 91 smještenih između petlji 86, 87 kako bi se postiglo nepropusno brtvljenje.
A flash column was packed with silica gel and wet with 8:2 heptane/IPAc (1.5L). 
Flash stupac je bio napunjen sa silikagelom i navlažen s 8:2 heptanom/IPAc (1.5 L).
According to another aspect, the invention provides a method for the prevention of the undesirable side effects associated with antipsychotic or antidepressant agents. 
Prema drugom aspektu, izum opisuje postupak za prevenciju nepoželjnih nuspojava povezanih s antipsihotičkim ili antidepresivnim agensima.
reducing the volume of the solution of CEM-101 by evaporation; and stirring the water during addition of the solution of CEM-101. 
reduciranje volumena otopine CEM-101 evaporacijom; i miješanje vode tijekom dodavanja otopine CEM-101.
-COOR7, where R7 is as previously defined; provided that at least one of A and R5 is defined as A = CH2-R' and/or R5 = R'. 
COORT, gdje je R7 definiran kao gore; uz uvjet da je najmanje jedan od A i R5 definiran kao A = CH»-R'i/ii R5 =R'.
A solid pharmaceutical composition comprising the SGLT-2 inhibitor 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, metformin hydrochloride and one or more pharmaceutical excipients, wherein the SGLT-2 inhibitor is present in a dosage strength of 5 mg or 12.5 mg, and wherein metformin hydrochloride is present in a dosage strength of 500 mg, 850 mg or 1000 mg, and wherein the solid pharmaceutical composition comprises copovidone as a binder. 
Kruti farmaceutski sastav, naznačen time, da obuhvaća SGLT-2-inhibitor 1-kloro-4-(B-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran-3-iloksi)-benzil]-benzen, metformin-hidroklorid i jedno ili više farmaceutskih pomoćnih sredstava, pri čemu je SGLT-2-inhibitor prisutan u jačini doze od 5 mg ili 12,5 mg, i gdje je metformin-hidroklorid prisutan u jačini doze od 500 mg, 850 mg ili 1000 mg, i pritom kruti farmaceutski sastav obuhvaća kopovidon kao vezivno sredstvo.
A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound according to claims 1 or 2 and a pharmaceutically acceptable vehicle. 
Sastav koji sadrži učinkovitu količinu spoja ili farmaceutski prihvatljivu sol spoja prema zahtjevima 1 ili 21 farmaceutski prihvatljivog nosača.
The solvent was evaporated; the residue was crystallised from acetonitrile, giving the product hydrochloride as a pale pink crystalline solid (8.16 g, 92%); 
Otapalo je otpareno a talog je kristaliziran iz acetonitrila, čime je dobiven hidroklorid produkta u obliku blijedo-roze kristalne krutine (8.16 g, 92 %);
The method according to claim 12, wherein the glaze coating is applied in a printing, more particularly screen printing, casting, injecting, spraying, spreading or dipping process or in a combination of at least two of the stated processes. 
Postupak prema bilo kojem od zahtjeva 11 do 20, naznačen time što se premaz od glazure primjenjuje u tiskarskom postupku, posebice u sitotisku, lijevanju, ubrizgavanju, raspršivanju, postupku četkanja ili postupku uranjanja ili u kombinaciji najmanje dva navedena postupka.
Unless otherwise indicated, the term “alkynyl” as used herein by itself or as part of another group refers to straight or branched chains of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons with one or more triple bonds in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like. 
Osim ako nije drugačije naznačeno, termin "alkinil" kao što se ovdje upotrebljava samostalno ili kao dio druge skupine odnosi se na ravne ili razgranate lance od 2 do 20 ugljika, poželjno 2 do 12 ugljika i još poželjnije 2 do 8 ugljika sa jednom ili više trostrukih veza u uobičajenom lancu, kao što su 2-propinil, 3-butinil, 2-butinil, 4-pentinil, 3-pentinil, 2-heksinil, 3-heksinil, 2-heptinil, 3-heptinil, 4-heptinil, 3-oktinil, 3-noninil, 4-decinil, 3-undecil, 4-dodecinil i slično.
one or more of the lipids in the lipid fraction are labeled with the label; 
(b) miješanje lipoproteinskih kompleksa s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
addition of brewer's yeast or yeast mother or a mix of the two to said compound of thermoplastic polymers to obtain a final product containing brewer's yeast or yeast mother or a mix of the two, and 
dodatak pivskog kvasca ili kvasca ili mješavina tih dvaju spomenutim termoplastičnim polimerima za dobivanje završnog proizvoda koji sadrži pivski kvasac ili kvasac ili mješavinu tih dvaju, i
A recombinant anti-a4 antibody molecule, or an a4-binding fragment thereof, comprising a variable heavy chain and a variable light chain, wherein: 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, naznačena time, da obuhvaća varijabilni jaki lanac i varijabilni slabi lanac, pri čemu:
is selected from the group consisting of —OR8, —NR8R9; wherein the R5 group has a molecular weight of less than 200 atomic mass units; 
Rs je izabran iz skupine koja se sastoji od -OR*, -NR*R"; gdje Rs skupina ima molekularnu masu koja je manja od 200 atomskih jedinica mase;
the final solids content of the aqueous suspension obtained after step d) is from 80 to 85 wt%. 
- konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) je od 80 do 85 % tež..
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the tool attached to the free end of the third articulated telescopic segment (11) defined by a metal detector (17). THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claim 1, characterised in that the tool fitted to the free end of the third articulated telescopic segment (11) is defined by an air blower system (18). 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što je alat pričvršćen na slobodni kraj trećeg uzglobljenog teleskopskog segmenta (11) definiran detektorom metala ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevom 1, naznačena time što je alat prigrađen na slobodni kraj trećeg uzglobljenog teleskopskog segmenta (11) definiran sustavom za puhanje zraka (18).
Cocoa-derived material according to any of claims 1 to 5, wherein said cocoa extract is obtained from non-defatted cocoa beans, preferably from non-fermented, non-defatted cocoa beans. Cocoa-derived material according to any of claims 1 to 6, wherein said cocoa extract comprises more than 35wt% of polyphenols. 
Tvar dobivena iz kakaa u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se dotični ekstrakt kakaa dobiva iz neodmašćenih zrna kakaovca, poželjno je nefermentiranih, neodmašćenih zrna kakaovca.
The aq. solution was washed with ether, cooled in ice bath, and neutralized with 1 N HCl (8 mL). 
Vodenu otopinu ispere se eterom, ohladi u ledenoj kupelji, te neutralizira s 1 N HC1 (8 ml).
A controlled release oral pharmaceutical composition according to claim 1, wherein said controlled release oral pharmaceutical composition comprises from about 20% to about 60% by weight of rifamycin SV. 
Farmaceutski pripravci prema prethodnim patentnim zahtjevima, u kojima je količina sadržanog rifamicina SV od 20 do 90 % masenog udjela.
A pharmaceutical composition comprising an antibody of any one of claims 1 to 15 and/or a conjugate of claim 18 or 19, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 i farmaceutski prihvatljivi nosač.
Clause 13. The minimally invasive skin treatment device of clause 1, wherein the tool is a needle, the device further comprising: a pump; and, a source of injectable fluids in fluid communication with said pump, wherein the needle is in fluid communication with the pump, the needle being configured to inject the injectable fluids into a tissue disposed in the recessed area. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 1, naznačen time, da je alat igla, (1001), uređaj dodatno obuhvaća: pumpu i izvor injekcijskih tekućina u fluidnoj vezi s navedenom crpkom, pri čemu je igla fluidno povezana s pumpom, igla je konfigurirana tako da se mogu uštrcavati tekućine za injektiranje u tkivo smješteno u udubljenom području.
Optionally, controller 80 and other electrical or electronic circuitry or components could be manufactured, in whole or in part, into a circuit board that could be installed in a housing for operable use with apparatus 10. 
Po želji, kontrolor 80 i druga električna ili elektronska kola ili komponente mogu se ugraditi, u cjelini ili djelomično, u jednu štampanu ploču koja se može unijeti u neko kućište za povezivanje s uređajem 10.
Additionally, the bore of the juicer 111 may be accessed by removing cap element 105 . 
Dodatno, zapremina sokovnika 111 može biti dostupna uklanjanjem poklopca 105.
STEP D: cooling the mixture prepared in STEP C; to yield a precipitate of the compound of formula (I-S). 
KORAK D: hlađenje smjese pripremljene u KORAKU C; da se dobije talog spoja formule (I-S).
A method according to any of claims 1 to 7 or 9 to 13, wherein the binder is provided in dry form. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 7 ili 9 do 13, pri čemu je vezivno sredstvo dobiveno u suhom obliku.
Asenapine is a compound for use in the treatment of central nervous system disorders, in particular schizophrenia. 
Asenapin je spoj koji se rabi u liječenju poremećaja središnjeg živčanog sustava, posebice shizofrenije.
Figure 2 is a plan view of the interior of a poultry shed in which the process according to the invention is implemented; 
Postupak sukladno Zahtjevu 12 u kojem se prostor za skladištenje goriva (7) sastoji od otvorenog skladišnog prostora susjednog aparatu za spaljivanje.
Combined preparation according to claim 11, wherein the inositol phosphate is inositol hexaphosphate, preferably myo -inositol hexaphosphate. 
Kombinirani pripravak prema zahtjevu 10, naznačen time što inozitol fosfat je inozitol heksafosfat, poželjno myo-inozitol heksafosfat.
The reaction is concentrated in vacuo with toluene and the resulting oil is purified by chromatography on silica eluting with iso-hexane/ethyl acetate (3:1) to yield [2-methyl-1-(4-nitro-benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid methyl ester. 
Reakcijsku smjesu se koncentrira u vakuumu s toluenom i dobiveno ulje se očisti kromatografijom na silika gelu ispirući s izo-heksan/etil acetatom (3:1), čime se dobije metil ester [2-metil-1-(4-nitro-benzil)-1H-pirolo[2,3-b]piridin-3-il]-octene kiseline.
W is a group of formula (Wc) 
W je skupina formule (WC)
The pharmaceutical composition of claim 5 wherein Formulae 11, 22, and 33 are represented by the following structures: 
Oralni oblik doziranja prema zahtjevu 1 naznačen time što Formula 1, Formula 2 i Formula 3 odgovaraju slijedećim strukturama:
Even though the symptoms are not immediately severe, over time, uncontrolled high blood sugar levels can damage the smaller blood vessels, leading to complications including irreversible damage to the eyes and kidneys. 
Premda simptomi nisu odmah teški, nekontrolirano visoke razine šećera u krvi mogu s vremenom oštetiti manje krvne žile i prouzročiti komplikacije, uključivši nepovratno oštećenje očiju i bubrega.
The compound for use in a method of treatment according to claim 11 or the use of claim 12, the method further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is administered to the subject concurrently with the compound. The compound for use in a method of treatment according to claim 11 or the use of claim 12, the method further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is administered to the subject sequentially with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 8 ili uporaba prema zahtjevu 9, naznačen(a) time, da nadalje obuhvaća davanje dodatnog terapeutskog sredstva pojedincu, pri čemu je opcijski dodatno terapeutsko sredstvo neki drugi inhibitor Raf-kinaze ili je inhibitor za sljedeće: MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, C-kinaza proteina, MAP-kinaza, MAPK-kinaza ili ERK, te se dodatno terapeutsko sredstvo daje pojedincu istovremeno sa spojem.
The pharmaceutical composition of claim 6, wherein said anti-cancer therapy agent is at least one agent selected from the group consisting of radiotherapy (XRT) agents, cytotoxic agents, targeted agents, and adjunctive agents. 
Farmaceutski sastav iz patentnog zahtjeva 6, pri čemu je navedeni terapijski agens protiv raka najmanje jedan agens odabran iz grupe koja se sastoji od agenasa za radioterapiju (XRT), citotoksičnih agenasa, ciljanih agenasa i adjunktivnih agenasa.
A compound selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine:
Then, the bottom of the filtration plate are sealed, 50ul of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. 
Zatim, dno filtracijske ploče je zatvoreno, 50 ul Optiphase Supermix je dodano u svaku posudicu, gornji dio ploče je zatvoren i ploče su podvrgnute brojenju u Trilux_MicroBeta scintilacijskom brojaču.
When the reagent used is a carboxylic acid halide, an exemplary procedure (as shown in FIG. 18) is as follows. 
Kada je reagens koji se koristi halogenid karboksilne kiseline, slijedi postupak koji je prikazan kao primjer (kao što je prikazano na slici 18).
Spraying speed of the pelletizing liquid was set at 250 ml/min, pressure of spraying air was 3.5 bar. 
Brzina raspršivanja tekućine za granuliranje bila je postavljena na 250 ml/min, a tlak zraka za raspršivanje bio je 3,5 bar.
A host cell wherein a nucleic acid encoding the heavy chain of the antibody of claim 2 or 3 and a nucleic acid encoding the light chain of the antibody of claim 2 or 3 have been introduced into the host cell. 
Stanica domaćina pri čemu su nukleinska kiselina koja kodira teški lanac antitijela prema zahtjevu 2 ili 3 1 nukleinska kiselina koja kodira laki lanac antitijela prema zahtjevu 2 ili 3 unesene u stanicu domaćina.
Fc is the immunoglobulin hinge region and CH2, CH3 immunoglobulin heavy chain constant domains; and L1, L2, L3, and L4 are amino acid linkers; wherein 
Fc je imunoglobulinska zglobna regija i CH2, CH3 imunoglobulinska konstantna domena teških lanaca; i, L2, L3, i L4 su amino kiselinske poveznice;
Use of an effective amount of a conjugate molecule as defined in anyone of claims 3 to 9 or a compound as defined in any one of claims 1 or 2 for the preparation of a medicament for killing or inhibiting growth of cells comprising contacting target cells or tissue containing target cells. 
Upotreba djelotvorne količine molekule konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9 ili spoja u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, u pripravi medikamenta za ubijanje ili inhibiranje rasta stanica, naznačena time što se sastoji u stavljanju u kontakt molekule konjugata ili spoja s ciljanim stanicama ili tkivom koje sadrži ciljane stanice.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 6, gdje formulacija matrice s produljenim otpuštanjem nakon skladištenja na 25%C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, kada je mjerenje provedeno u USP aparatu 1 (košara) pri 100 okr/min u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37*C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The system according to claim 14, wherein the sealing material has a thickness of 0.3 mm to 2.5 mm. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 15 do 18, u kojemu ima materijal za brtvljenje (8) debljinu od 0.3 mm do 2.5 mm, poželjno 0.5 mm do 2 mm.
in the Fasted State (Population: Full Analysis) 
Populacija: potpuna analiza (narasičeno stanje) FoBR A
the method comprising: aa) dissolving the compound of the formula (III) and/or (II): 
(II) i b) najmanje jednu fosfatnu sol i izborno NaCI; naznačen time što se postupak sastoji u: aa) otapanju spoja formule (III) i/ili (ID):
The process of paragraph 67, wherein said base is selected from the group consisting of triethylamine; 1,5-diazabicyclo[4,3,0]non-5-ene; 1,4-diazabicyclo[2,2,2]octane; and 1,8-diazabicyclo[5,4,0]undec-7-ene. 
Postupak u skladu s patentnim zahtjevom 57, naznačen time što navedenu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.0]lundec-7-en.
The method of E 34, wherein the susceptibility diagnosis is based on the patient having a systemic autoimmune disease. 
Antagonist za uporabu u skladu sa zahtjevom 34, naznačen time, da je dijagnoza osjetljivosti zasnovana na tome da pacijent ima sistemsku autoimunu bolest.
The method according to claim 7, CHARACTERIZED IN THAT 2.5 to 4 weight% of solid mineral alkaline in powder form and 0.5 to 1 weight% of concentrated mineral acid is used, based on the weight of the ammonium nitrate-based particles. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se upotrebljava 2,5 do 4 % težinskih udjela krute mineralne lužine u praškastom obliku i 0,5 do 1 % težinskih udjela koncentrirane mineralne kiseline, u odnosu na težinu čestica na bazi amonijeva nitrata.